Healthcare
Zhengye Biotechnology Holding Limited(ZYBT)
Live Price
Offline$0.75
-3.23% today
1Y Change
-89.16%
Window
Jun 23, 2025 → Jun 15, 2026
- Market Cap
- $320.00M
- Revenue Growth
- -37.6%
- EPS Growth
- -100.0%
- Dividend Yield
- 0.0%
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zhengye Biotechnology Holding Limited (ZYBT) is a Healthcare stock with a market cap of $320.00M and listed on NASDAQ. The stock last traded around $0.75 and down 89.2% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -37.6%, EPS growth of -100.0%, a dividend yield of 0.0%. What stands out right now is revenue -37.6%, EPS -100.0%, free cash flow -94.7% with operating margin -58.7% and ROIC -17.9%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZYBT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-37.6% vs +7.6% peer median
Operating Margin
Below sector median
-58.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -37.6% and EPS is at -100.0%, with operating margin around -58.7%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZYBT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZYBT Max Drawdown
-94.39%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZYBT and SPY.
Company Overview
Zhengye Biotechnology Holding Limited
NASDAQ Capital Market
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
- Leadership
- Songlin Song
- IPO Date
- Jan 7, 2025
- Employees
- 278
- Street Address
- No.1 Lianmeng Road
- Mailing
- Jilin, 132101
- Region
- Jilin, CN
- Reporting Currency
- USD
- Investor Line
- 86 432 6304 7008
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 2.8
- Price/Book
- —
Growth
- Revenue
- -37.6%
- EPS
- -100.0%
- Free Cash Flow
- -94.7%
Profitability
- Gross Margin
- 20.5%
- Operating Margin
- -58.7%
- Net Margin
- -60.0%
- ROE
- -26.1%
- ROIC
- -17.9%
Balance Sheet
- Debt/Equity
- 0.30
- Current Ratio
- 1.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.